Compare GDV & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | DYN |
|---|---|---|
| Founded | 2003 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | N/A | 2020 |
| Metric | GDV | DYN |
|---|---|---|
| Price | $29.22 | $18.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 92.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.10 | $8.25 |
| 52 Week High | $29.46 | $25.00 |
| Indicator | GDV | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 50.12 |
| Support Level | $26.24 | $18.32 |
| Resistance Level | $29.46 | $19.65 |
| Average True Range (ATR) | 0.37 | 1.07 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 92.54 | 26.66 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.